公开(公告)号：US20190040022A1

公开(公告)日：2019-02-07

申请号：US16068553

申请日：2017-01-05

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Keisuke HIRAI ,  Takashi ISHIKAWA

IPC: C07D263/52 ,  C07D277/60 ,  C07D413/06 ,  A61P25/00

Abstract: The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.

公开(公告)号：US20210130305A1

公开(公告)日：2021-05-06

申请号：US16935531

申请日：2020-07-22

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Keisuke HIRAI ,  Takashi ISHIKAWA

IPC: C07D263/52 ,  A61K31/428 ,  A61K31/423 ,  A61P25/00 ,  C07D277/60 ,  C07D413/06

Abstract: The present invention provides a prophylactic or therapeutic agent for an autism spectrum disorder containing compound (I) having melatonin receptor affinity. A compound represented by the formula: wherein each symbol is as described in the specification, or a salt thereof.